drugset
drugset / Trial / NCT05726110

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

NCT05726110 ↗

Phase 3 Recruiting 50 enrolled Shanxi Bethune Hospital Antengene Corporation · collab
NaSingle-groupOpen-labelTreatment

Summary

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Timeline

Start
2023-01-29
Primary completion
2024-12-10
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Selinexor Other / unclassified 60 mg Oral
Background Aclacinomycin Unknown 20 mg —
Background Cytarabine Small molecule 10 mg/m2 Subcutaneous
Background Cytarabine Small molecule 100 mg/m2 Subcutaneous
Background Cytarabine Small molecule 200 mg/m2 Subcutaneous
Background Daunorubicin Small molecule 40 mg/m2 —
Background Granulocyte colony-stimulating factor Protein / enzyme biologic 5 ug/kg —
Background Homoharringtonine Small molecule 2 mg/m2 —

Indications

acute myeloid leukemia